The 2022 American Society of Clinical Oncology (ASCO) Annual Meeting was held on June 3-7 in Chicago, Illinois. This is the most significant event for people working in oncology in both clinical practice and clinical research. This year's ASCO scientific program committee members reviewed over 6,000 abstracts, and hundreds were presented as oral presentations or posters during the meeting. A significant number of these reported potentially practice-changing results that may change the current treatment guidelines and thus influence the design of clinical trial protocols.
Several abstracts included long-term follow-up results for previously reported studies, providing important survival and safety updates. Negative results traditionally do not gain much attention, but if a closely watched large study does not show benefit, it is still an important piece of information and contributes just as much to our knowledge of the disease as a positive result. In this white paper, we will discuss those presentations and abstracts that may change diagnostic and treatment approaches in oncology and what they could mean for the future of clinical research.